oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes of tirzepatide for patients with clinical practice Oral Semaglutide and Cardiovascular Outcomes

When that happens, damage builds

Thus, the fact that BPC 157 has the apparent ability to counteract corticosteroid aggravation (Krivic et al

Tirzepatide (GLP-1) : This is a multi-action GLP-1 receptor agonist

Anti-inflammatory effects: Downregulates pro-inflammatory cytokines (IL-6, TNF-, IL-1) and reduces oxidative stress Gut barrier integrity: Promotes repair of tight junctions, limiting leaky gut and preventing translocation of inflammatory molecules Angiogenesis and collagen production: Enhances growth of new blood vessels and collagen fibers, accelerating tissue repair after injury or chronic inflammation How BPC-157 decreases inflammation 3 Suppresses pro-inflammatory pathways: Inhibits NF-B signaling, reducing the cascade of inflammatory cytokines Enhances anti-inflammatory factors: Upregulates protective growth factors such as VEGF (vascular endothelial growth factor) and TGF- Reduces oxidative stress: Neutralizes reactive oxygen species (ROS), decreasing tissue damage in the inflamed oral mucosa or stomach lining Restores tissue balance: Unlike broad anti-inflammatories (NSAIDs), BPC-157 doesnt shut down inflammation entirely

[14] GLP-1 medications at doses licensed for diabetes often produce more modest weight loss of 2-6kg